{"id":3165,"date":"2018-01-25T17:41:13","date_gmt":"2018-01-25T22:41:13","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/"},"modified":"2026-09-24T00:09:50","modified_gmt":"2026-09-24T04:09:50","slug":"gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/","title":{"rendered":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing"},"content":{"rendered":"\n<strong>Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Julio J. Benedicto au poste de Vice-Pr\u00e9sident Marketing.\n\nM. Benedicto poss\u00e8de plus de 20 ans d\u2019exp\u00e9rience en tant que consultant en strat\u00e9gie dans les sciences de la vie, tant en Europe qu\u2019aux \u00c9tats-Unis. Son expertise s\u2019\u00e9tend de la d\u00e9finition et l\u2019ex\u00e9cution de strat\u00e9gies de marketing et de vente, la planification et la mise en \u0153uvre de lancements de produits, \u00e0 la mise en place d\u2019infrastructures commerciales. Ses clients incluaient \u00e0 la fois les principaux laboratoires pharmaceutiques et soci\u00e9t\u00e9s de biotechnologies de premier plan, mais \u00e9galement des laboratoires de m\u00e9decine de sp\u00e9cialit\u00e9 dans le cadre de la mise sur le march\u00e9 de leur premier produit, souvent dans des maladies rares.\n\nAu sein de Gensight Biologics, Julio Benedicto supervisera la strat\u00e9gie produit globale, la veille sectorielle, ainsi que la d\u00e9finition et le d\u00e9ploiement des strat\u00e9gies globales de pr\u00e9-commercialisation et de lancement des candidats m\u00e9dicaments de la Soci\u00e9t\u00e9, et notamment de GS010, actuellement en fin de phase III de d\u00e9veloppement clinique. Julio Benedicto int\u00e8gre le comit\u00e9 de direction et sera bas\u00e9, dans un premier temps, \u00e0 Paris.\n\n\u00ab La grande exp\u00e9rience de Julio \u00e0 d\u00e9velopper des strat\u00e9gies globales de marketing et de lancement de nouveaux m\u00e9dicaments, en particulier dans les maladies rares, constitue un atout majeur pour l\u2019\u00e9quipe dirigeante de GenSight Biologics. \u00bb a d\u00e9clar\u00e9 <strong>Bernard \u00a0Gilly<\/strong>, cofondateur et Directeur G\u00e9n\u00e9ral. \u00ab Alors que les premiers r\u00e9sultats de phase III de GS010 sont attendus dans seulement quelques mois, il est temps de transformer la Soci\u00e9t\u00e9 et de se donner les moyens de notre ambition \u00e0 commercialiser en propre. \u00bb\n\nAvant de rejoindre GenSight Biologics, Julio Benedicto \u00e9tait Principal chez IQVIA, bas\u00e9 \u00e0 Munich, o\u00f9 il \u00e9tait membre des p\u00f4les d\u2019excellence Brand and Commercial Strategy et Launch Excellence. Auparavant, il a travaill\u00e9 chez Monitor Group (aujourd\u2019hui Monitor Deloitte) \u00e0 New York et Londres, ainsi que chez Booz &amp; Company (aujourd\u2019hui Strategy &amp;, filiale consulting de PwC) \u00e0 Berlin.\n\nJulio Benedicto est titulaire d\u2019un B.A. en \u00c9conomie \u00ab summa cum laude \u00bb de l\u2019Universit\u00e9 Yale (USA), ainsi que d\u2019un M.A. et d\u2019un M.Phil. en \u00c9conomie de la Yale Graduate School of Arts and Sciences.\n\n\u00ab Je suis particuli\u00e8rement enthousiaste de rejoindre GenSight Biologics \u00e0 un moment aussi important dans le d\u00e9veloppement de la Soci\u00e9t\u00e9. \u00bb, a d\u00e9clar\u00e9 <strong>Julio Benedicto<\/strong>. \u00ab Transformer la promesse d\u2019une avanc\u00e9e scientifique majeure en un traitement innovant qui pourrait changer la vie des patients est un d\u00e9fi aussi complexe que gratifiant. J\u2019ai h\u00e2te de collaborer avec les \u00e9quipes talentueuses de GenSight pour relever ce d\u00e9fi ensemble. \u00bb\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Julio J. Benedicto au [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3165","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Julio J. Benedicto au [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-25T22:41:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:50+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing\",\"datePublished\":\"2018-01-25T22:41:13+00:00\",\"dateModified\":\"2026-09-24T04:09:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/\"},\"wordCount\":705,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/\",\"name\":\"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-01-25T22:41:13+00:00\",\"dateModified\":\"2026-09-24T04:09:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics","og_description":"Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Julio J. Benedicto au [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/","og_site_name":"GenSight Biologics","article_published_time":"2018-01-25T22:41:13+00:00","article_modified_time":"2026-09-24T04:09:50+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing","datePublished":"2018-01-25T22:41:13+00:00","dateModified":"2026-09-24T04:09:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/"},"wordCount":705,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/","name":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2018-01-25T22:41:13+00:00","dateModified":"2026-09-24T04:09:50+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-nomme-julio-benedicto-au-poste-de-vice-president-marketing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics nomme Julio Benedicto au poste de Vice-Pr\u00e9sident Marketing"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3165"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3165"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3165"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3165"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3165"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}